MX379776B - Derivados de diamino piridina para usarse en el tratamiento de dermatitis atópica o psoriasis. - Google Patents
Derivados de diamino piridina para usarse en el tratamiento de dermatitis atópica o psoriasis.Info
- Publication number
- MX379776B MX379776B MX2018006495A MX2018006495A MX379776B MX 379776 B MX379776 B MX 379776B MX 2018006495 A MX2018006495 A MX 2018006495A MX 2018006495 A MX2018006495 A MX 2018006495A MX 379776 B MX379776 B MX 379776B
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- pyridine derivatives
- psoriasis
- diamino pyridine
- atopic dermatitis
- Prior art date
Links
- ZZYXNRREDYWPLN-UHFFFAOYSA-N pyridine-2,3-diamine Chemical class NC1=CC=CN=C1N ZZYXNRREDYWPLN-UHFFFAOYSA-N 0.000 title abstract 2
- 206010012438 Dermatitis atopic Diseases 0.000 title 1
- 201000004681 Psoriasis Diseases 0.000 title 1
- 201000008937 atopic dermatitis Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención describe derivados novedosos de diamino piridina que uestran propiedades de modulación de JAK. La presente invención también se refiere a composiciones farmacéuticas que comprenden estos nuevos compuestos, métodos de uso de dichos compuestos en el tratamiento de diversas enfermedades y trastornos que son susceptibles a la modulación de JAK, y procedimientos para preparar los compuestos descritos más adelante.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15196542 | 2015-11-26 | ||
| PCT/IB2016/057105 WO2017089985A1 (en) | 2015-11-26 | 2016-11-24 | Diamino pyridine derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018006495A MX2018006495A (es) | 2018-08-15 |
| MX379776B true MX379776B (es) | 2025-03-11 |
Family
ID=54705130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018006495A MX379776B (es) | 2015-11-26 | 2016-11-24 | Derivados de diamino piridina para usarse en el tratamiento de dermatitis atópica o psoriasis. |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US10570096B2 (es) |
| EP (2) | EP3757097B1 (es) |
| JP (1) | JP6634157B2 (es) |
| KR (1) | KR102097878B1 (es) |
| CN (2) | CN108349937B (es) |
| AU (1) | AU2016359438B2 (es) |
| BR (1) | BR112018009540A2 (es) |
| CA (1) | CA3005159A1 (es) |
| CL (1) | CL2018001370A1 (es) |
| CO (1) | CO2018005354A2 (es) |
| CR (1) | CR20180285A (es) |
| CU (1) | CU24506B1 (es) |
| CY (1) | CY1123543T1 (es) |
| DK (1) | DK3380465T3 (es) |
| DO (1) | DOP2018000127A (es) |
| EA (1) | EA035899B1 (es) |
| EC (1) | ECSP18041731A (es) |
| ES (2) | ES2916582T3 (es) |
| HR (1) | HRP20201662T1 (es) |
| HU (1) | HUE052345T2 (es) |
| IL (1) | IL259360B (es) |
| LT (1) | LT3380465T (es) |
| MX (1) | MX379776B (es) |
| MY (1) | MY195905A (es) |
| PE (1) | PE20181071A1 (es) |
| PH (1) | PH12018501019B1 (es) |
| PL (2) | PL3380465T3 (es) |
| PT (2) | PT3757097T (es) |
| RS (1) | RS60946B1 (es) |
| RU (2) | RU2730007C2 (es) |
| SA (1) | SA518391657B1 (es) |
| SG (1) | SG11201803760VA (es) |
| SI (1) | SI3380465T1 (es) |
| WO (1) | WO2017089985A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3380465T3 (da) * | 2015-11-26 | 2020-10-26 | Novartis Ag | Diaminopyridinderivativer |
| KR102630669B1 (ko) | 2019-01-11 | 2024-01-30 | 노파르티스 아게 | 화농성 한선염 치료를 위한 lta4h 억제제 |
| TW202342048A (zh) | 2022-02-28 | 2023-11-01 | 瑞士商諾華公司 | 使用ｌｏｕ０６４治療化膿性汗腺炎之方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| ME00811B (me) * | 2006-12-08 | 2012-03-20 | Novartis Ag | JEDINJENJA l KOMPOZICIJE KAO INHIBITORI PROTEIN KINAZE |
| JP5569956B2 (ja) | 2007-03-16 | 2014-08-13 | ザ スクリプス リサーチ インスティテュート | 接着斑キナーゼのインヒビター |
| WO2010058846A1 (ja) * | 2008-11-21 | 2010-05-27 | アステラス製薬株式会社 | ４，６-ジアミノニコチンアミド化合物 |
| AU2009320683B2 (en) | 2008-11-28 | 2012-07-19 | Kowa Company, Ltd. | Pyridine-3-carboxyamide derivative |
| EP2565193B1 (en) | 2009-01-23 | 2014-03-19 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
| US8415381B2 (en) * | 2009-07-30 | 2013-04-09 | Novartis Ag | Heteroaryl compounds and their uses |
| WO2012061428A2 (en) | 2010-11-01 | 2012-05-10 | Portola Pharmaceuticals, Inc. | Nicotinamides as jak kinase modulators |
| US9198911B2 (en) | 2010-11-02 | 2015-12-01 | The Trustees Of Columbia University In The City Of New York | Methods for treating hair loss disorders |
| WO2014060371A1 (en) | 2012-10-19 | 2014-04-24 | F. Hoffmann-La Roche Ag | Inhibitors of syk |
| EP2922846B1 (en) * | 2012-11-08 | 2018-10-03 | Bristol-Myers Squibb Company | Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn-alpha |
| WO2014074660A1 (en) * | 2012-11-08 | 2014-05-15 | Bristol-Myers Squibb Company | ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNα RESPONSES |
| PE20150953A1 (es) * | 2012-11-08 | 2015-06-20 | Bristol Myers Squibb Co | Compuestos de piridilo sustituidos con heteroarilo utiles como moduladores de cinasa |
| US20140343034A1 (en) | 2013-04-25 | 2014-11-20 | Japan Tobacco Inc. | Skin barrier function improving agent |
| WO2014181287A1 (en) | 2013-05-09 | 2014-11-13 | Piramal Enterprises Limited | Heterocyclyl compounds and uses thereof |
| WO2014203132A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Substituted benzopyran compounds, compositions and uses thereof |
| JP2015014960A (ja) | 2013-07-05 | 2015-01-22 | ソニー株式会社 | 情報処理装置、および記憶媒体 |
| CA2926361A1 (en) | 2013-10-24 | 2015-04-30 | Abbvie Inc. | Jak1 selective inhibitor and uses thereof |
| CA2969590A1 (en) | 2014-12-03 | 2016-06-09 | Rxi Pharmaceuticals Corporation | Methods for the treatment of alopecia areata utilizing gene modulation approaches |
| DK3380465T3 (da) * | 2015-11-26 | 2020-10-26 | Novartis Ag | Diaminopyridinderivativer |
-
2016
- 2016-11-24 DK DK16805218.1T patent/DK3380465T3/da active
- 2016-11-24 PH PH1/2018/501019A patent/PH12018501019B1/en unknown
- 2016-11-24 KR KR1020187014470A patent/KR102097878B1/ko not_active Expired - Fee Related
- 2016-11-24 MY MYPI2018701770A patent/MY195905A/en unknown
- 2016-11-24 AU AU2016359438A patent/AU2016359438B2/en not_active Ceased
- 2016-11-24 CN CN201680065351.8A patent/CN108349937B/zh not_active Expired - Fee Related
- 2016-11-24 ES ES20185507T patent/ES2916582T3/es active Active
- 2016-11-24 WO PCT/IB2016/057105 patent/WO2017089985A1/en not_active Ceased
- 2016-11-24 EP EP20185507.9A patent/EP3757097B1/en active Active
- 2016-11-24 CA CA3005159A patent/CA3005159A1/en not_active Abandoned
- 2016-11-24 US US15/778,783 patent/US10570096B2/en active Active
- 2016-11-24 CN CN202110135667.2A patent/CN112851578A/zh not_active Withdrawn
- 2016-11-24 RU RU2018122953A patent/RU2730007C2/ru active
- 2016-11-24 EA EA201891258A patent/EA035899B1/ru not_active IP Right Cessation
- 2016-11-24 SI SI201630959T patent/SI3380465T1/sl unknown
- 2016-11-24 CR CR20180285A patent/CR20180285A/es unknown
- 2016-11-24 PL PL16805218T patent/PL3380465T3/pl unknown
- 2016-11-24 HR HRP20201662TT patent/HRP20201662T1/hr unknown
- 2016-11-24 LT LTEP16805218.1T patent/LT3380465T/lt unknown
- 2016-11-24 CU CU2018000044A patent/CU24506B1/es unknown
- 2016-11-24 JP JP2018527091A patent/JP6634157B2/ja not_active Expired - Fee Related
- 2016-11-24 PT PT201855079T patent/PT3757097T/pt unknown
- 2016-11-24 RS RS20201234A patent/RS60946B1/sr unknown
- 2016-11-24 HU HUE16805218A patent/HUE052345T2/hu unknown
- 2016-11-24 PT PT168052181T patent/PT3380465T/pt unknown
- 2016-11-24 BR BR112018009540A patent/BR112018009540A2/pt not_active Application Discontinuation
- 2016-11-24 ES ES16805218T patent/ES2829052T3/es active Active
- 2016-11-24 SG SG11201803760VA patent/SG11201803760VA/en unknown
- 2016-11-24 PL PL20185507.9T patent/PL3757097T3/pl unknown
- 2016-11-24 MX MX2018006495A patent/MX379776B/es unknown
- 2016-11-24 EP EP16805218.1A patent/EP3380465B1/en active Active
- 2016-11-24 PE PE2018001004A patent/PE20181071A1/es unknown
- 2016-11-24 RU RU2020124922A patent/RU2020124922A/ru unknown
-
2018
- 2018-05-14 IL IL259360A patent/IL259360B/en active IP Right Grant
- 2018-05-21 DO DO2018000127A patent/DOP2018000127A/es unknown
- 2018-05-22 CL CL2018001370A patent/CL2018001370A1/es unknown
- 2018-05-22 CO CONC2018/0005354A patent/CO2018005354A2/es unknown
- 2018-05-23 SA SA518391657A patent/SA518391657B1/ar unknown
- 2018-05-31 EC ECIEPI201841731A patent/ECSP18041731A/es unknown
-
2020
- 2020-01-08 US US16/737,366 patent/US11274080B2/en active Active
- 2020-11-03 CY CY20201101039T patent/CY1123543T1/el unknown
-
2022
- 2022-02-22 US US17/677,538 patent/US20220177432A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123996T1 (el) | Υποκατεστημενα παραγωγα οξοπυριδινης | |
| JO3512B1 (ar) | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز | |
| MX391981B (es) | Derivados de benzooxazol como inmunomoduladores. | |
| MX389513B (es) | Compuestos heterocíclicos como inmunomoduladores. | |
| BR112017024384A2 (pt) | bactérias modificadas para reduzir hiperfenilalaninemia | |
| MX2017013562A (es) | Reguladores de microbioma y usos relacionados de los mismos. | |
| MX2019000588A (es) | Moduladores de la somatostatina y usos de los mismos. | |
| SG10201806849WA (en) | Cyclopropylamines as lsd1 inhibitors | |
| MX391725B (es) | Compuestos y metodos para tratamiento de afecciones neurologicas y cardiovasculares. | |
| CL2016002072A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| EP4556491A3 (en) | Therapeutic molecules | |
| UY37017A (es) | Inhibidores aza-bencimidazol de pad4 | |
| MX2018000352A (es) | 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b. | |
| MX389724B (es) | Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo | |
| MX2016013447A (es) | Heterociclilsulfonas heteroarilo sustituidas. | |
| MY180844A (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
| MX2018001592A (es) | Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos. | |
| BR112017024908A2 (pt) | usos terapêuticos da 4-cloroquinurenina | |
| UA117779C2 (uk) | Піразини як модулятори gpr6 | |
| TW201713686A (en) | Methods for preparing modified von Willebrand factor | |
| CY1123543T1 (el) | Παραγωγα διαμινοπυριδινης | |
| CL2016002321A1 (es) | Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios. | |
| MX2016013451A (es) | Heterociclilsulfonas arilo sustituidas. | |
| BR112017014229A2 (pt) | conjugado, composição, e, método para tratamento de um distúrbio. | |
| MX2016010967A (es) | Nuevas composiciones para tratar lesiones neuronales mecanicas. |